Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 24:2023:5617575.
doi: 10.1155/2023/5617575. eCollection 2023.

Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients

Affiliations

Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients

Jiangjie Sun et al. Behav Neurol. .

Abstract

Aim: To understand the degree of oncology patients' awareness of drug clinical trials and oncology patients' willingness to participate in drug clinical trials and the factors influencing them.

Methods: The differences in the relevant variables of patients' willingness to accept clinical trials were analyzed, and a descriptive analysis was done for the measurement data (mean and standard deviation). Pearson's correlation coefficient analysis was used to examine the correlation between willingness and the demographic variables. Stepwise regression analysis was used to explore the influencing factors of patients' willingness to accept clinical trials.

Results: There were no statistical differences in age, gender, education level, marital status, place of residence, monthly income, medical payment method, and treatment time (P > 0.05). Patients' willingness to accept drug clinical trials differed in their cognitive degree of clinical drug trials (P = 0.002). Patients' willingness to accept drug clinical trials differed in their experience in clinical trials (P < 0.001). The correlation difference was statistically significant. The willingness to accept drug clinical trials was negatively correlated with treatment time (R = -0.16, P < 0.05) and positively correlated with awareness of clinical trials and whether they had been subjects (R = 0.16 and 0.43, P < 0.05). Multiple regression analysis showed that patients' willingness was directly influenced by age, treatment time, and whether they had been subjects (F = 21.315, P < 0.001).

Conclusion: Age, treatment time, and whether they had been subjects were the direct influencing factors of patients' willingness. This study pointed out that hospitals should do a good job in the publicity of clinical trials of new drugs, expand publicity channels, increase publicity efforts, improve the awareness of clinical trials of the masses, and promote the enthusiasm of the masses to participate in clinical trials of drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Similar articles

References

    1. Liu Z. C., Li Z. X., Zhang Y., et al. Interpretation on the report of global cancer statistics 2020. Journal of Multidisciplinary Cancer Management . 2021;7(2):p. 14.
    1. Weorld Health Organization. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. February 2022, https://www.who.int/data/gho/data/themes/mortality-andglobal-health-esti....
    1. Zabora J., BrintzenhofeSzoc K., Curbow B., Hooker C., Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology . 2001;10(1):19–28. doi: 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6. - DOI - PubMed
    1. Cao W., Chen H. D., Yu Y. W., Li N., Chen W. Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal . 2021;134(7):783–791. doi: 10.1097/CM9.0000000000001474. - DOI - PMC - PubMed
    1. Zhao S., Lv C., Gong J., et al. Challenges in anticancer drug R&D in China. The Lancet Oncology . 2019;20(2):183–186. doi: 10.1016/S1470-2045(18)30865-9. - DOI - PubMed